Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer. Co.'s product candidate is sacituzumab govitecan (IMMU-132), an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer who previously received at least two prior therapies for metastatic disease. Co. also has other product candidates, which target solid tumors and hematologic malignancies in various stages of clinical and preclinical development, such as labetuzumab govitecan that binds the CEACAM5 antigen expressed on CRC and other solid cancers, and IMMU-140 for the treatment of hematologic malignancies. We show 47 historical shares outstanding datapoints in our IMMU shares outstanding history coverage, used to compute IMMU market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing IMMU market cap history over the course of time is important for investors
interested in comparing IMMU's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of IMMU versus a peer is one thing; comparing
IMMU market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like IMMU can fluctuate over the course of history.
With this page we aim to empower investors researching IMMU by allowing them to research the IMMU market cap history. |
Free IMMU Email Alerts:
Video: The Importance of Market Cap
